Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity
Movement Disorders2021Vol. 37(1), pp. 190–195
Citations Over TimeTop 10% of 2021 papers
Nurit Omer, Nir Giladi, Tanya Gurevich, Anat Bar‐Shira, Mali Gana‐Weisz, Tal Glinka, Orly Goldstein, Meir Kestenbaum, Jesse M. Cedarbaum, Omar S. Mabrouk, Kyle Fraser, Julia Shirvan, Avi Orr‐Urtreger, Anat Mirelman, Avner Thaler
Abstract
Low GCase activity does not explain the clinical phenotype or risk for prodromal PD in this cohort. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Related Papers
- → LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies(2016)48 cited
- → Function and dysfunction of leucine-rich repeat kinase 2 (LRRK2): Parkinson's disease and beyond(2015)39 cited
- → Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells(2021)11 cited
- → Selective inhibition of LRRK2 activity as an approach to the treatment of Parkinson's disease(2022)5 cited
- → ALTERATION OF BIOCHEMICAL PARAMETERS OF LYSOSOMAL ACTIVITY UPON INHIBITION OF LRRK2 KINASE ACTIVITY IN CELL LINES FROM PATIENTS WITH PARKINSON’S DISEASE ASSOCIATED WITH MUTATIONS IN THE GBA1 GENE(2023)